One airlifted in I-57 rollover crash in Shelby Co.
At approximately 8:06 a.m., Illinois State Police Troop 7 responded to I-57 southbound milepost 172 in Shelby County for the report of a single unit rollover traffic crash. As a result of the rollover, one person was airlifted to a local hospital with injuries.
Former Clark Co. student arrested in Indiana after bomb threat of former school
At approximately 8:28 a.m., all southbound lanes were closed at this location for air evac. At approximately 8:58 a.m., both State Police Troop 7 and Troop 9 were still on scene, and at 9:01 a.m., all lanes re-opened.
State Police are urging drivers to continue to use caution in this area and slow down until traffic returns to normal. There is no further information at this time.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Shift Towards Antibiotic Alternatives Drives Growth, New Vaccines and Diagnostics Revolutionize Poultry Health Management
The U.S. poultry medicine market, valued at USD 1.83 billion in 2024, is expected to soar to USD 3.11 billion by 2033, at a CAGR of 6.20%. High poultry consumption, reduced antibiotic use, and technological advances drive this growth. Key trends include antibiotic alternatives and efficient farming practices. U.S. Poultry Medicine Market Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The "U.S. Poultry Medicine Market Size, Share & Trends Analysis Report By Species (Chicken, Turkey, Ducks), By Product (Biologics, Pharmaceuticals), By Disease Type, By Route Of Administration, By Distribution Channel, And Segment Forecasts, 2025 - 2033" report has been added to U.S. poultry medicine market size was estimated at USD 1.83 billion in 2024 and is projected to reach USD 3.11 billion by 2033, growing at a CAGR of 6.20% from 2025 to 2033 The market is continuously growing, driven by high poultry consumption and market value, a shift towards antibiotic alternatives, and technological advancements in poultry healthcare. According to the USDA Economic Research Service, U.S. poultry products dominate both domestic and global meat markets, due to efficient production systems, advanced genetics, ample feed supply, and strong consumer demand. Between 2013 and 2022, broilers accounted for 67% of poultry sales, followed by eggs at 22% and turkeys at 11%, primarily for consumption. This surge in demand for poultry products directly translates into the need for efficient and sustainable poultry farming practices, necessitating comprehensive healthcare solutions to maintain the health and productivity of poultry flocks. The per capita consumption of poultry, from 2020 to 2024, is illustrated below in the chart:Growing concerns over antimicrobial resistance have prompted the U.S. poultry industry to reduce antibiotic use. Regulations like the Preservation of Antibiotics for Medical Treatment Act (PAMTA) and the Preventing Antibiotic Resistance Act (PARA) have restricted the use of medically important antibiotics in poultry and livestock. For decades, antibiotics have been widely used in livestock and poultry, as high-dose treatments for specific infections and as low-dose growth promoters in animal feed. In 2013, around 131,000 tons of antibiotics were used in food animals, a number projected to increase to nearly 200,000 tons by 2030 due to rising global demand. This shift has led to increased demand for alternative health management strategies, such as vaccines, probiotics, and herbal supplements, to ensure poultry health and in veterinary and animal nutrition technologies have significantly impacted the U.S. poultry pharmaceuticals market. The development of new vaccines, diagnostic tools, feed supplements, and other specialized healthcare products has enabled poultry producers to address a wider range of health challenges, improve flock performance, and enhance food safety. These innovations contribute to more efficient and sustainable poultry farming practices. Why should you buy this report? Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments. Competitive Landscape: Explore the market presence of key players worldwide. Future Trends: Discover the pivotal trends and drivers shaping the future of the global market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $1.83 Billion Forecasted Market Value (USD) by 2033 $3.11 Billion Compound Annual Growth Rate 6.2% Regions Covered United States Market Dynamics Market Driver Analysis High poultry consumption and market value Shift towards antibiotic alternatives Technological advancements in poultry healthcare Market Restraint Analysis Stringent regulatory compliance and approval processes U.S. Poultry Medicine Market Analysis Tools Industry Analysis - Porter's PESTEL Analysis Regulatory Framework Pricing Analysis Product Pipeline Analysis Estimated Poultry Population in U.S., 2024 Competitive Landscape Boehringer Ingelheim International GmbH Zoetis Services LLC Vaxxinova International BV Merck & Co., Inc. Elanco Ceva Sante Animale Phibro Animal Health Corporation Virbac Hipra Vetanco Kemin Industries, Inc. Market Participant Categorization Company Market Position Analysis/ Heat Map Analysis Participant's Overview Financial Performance Product Benchmarking Strategic Initiatives U.S. Poultry Medicine Market Report SegmentationSpecies Outlook (Revenue, USD Million, 2021 - 2033) Chicken Broiler Layer Turkey Ducks Others Product Outlook (Revenue, USD Million, 2021 - 2033) Biologics Vaccines Modified/ Attenuated Live Inactivated (Killed) Other Vaccines Other Biologics Pharmaceuticals Parasiticides Anti-infectives Anti-inflammatory Analgesics Others Medicated Feed Additives Disease Type Outlook (Revenue, USD Million, 2021 - 2033) Newcastle Disease Infectious Bronchitis Infectious Bursal Disease Coccidiosis Salmonella Marek's Disease Others Route of Administration Outlook (Revenue, USD Million, 2021 - 2033) Oral Injectable Topical Others Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033) Veterinary Hospitals & Clinics E-commerce Offline Retail Stores Others For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Poultry Medicine Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
13 minutes ago
- Yahoo
Health insurance companies have a problem — people are using their plans more
When medical insurance provider Centene (CNC) opened its books to investors on Friday, the company reported a surprising loss and an uptick in usage. The latter is a broader problem for the industry. In the second quarter, Centene reported an adjusted loss of $79 million and a "health benefits ratio" of 93%. Its benefits ratio, or the amount of its revenue derived from premiums that it pays out for medical care, jumped from 87.6% in the same quarter last year. Moves in that figure can have outsized effects on health insurers' financial performance. "Because of the narrow margins of our health plan business, relatively small changes in our HBR can create significant changes in our financial results," Centene wrote in its Q2 earnings report. And the problem is not isolated to Centene. Elevance Health (ELV), which offers plans including Blue Cross and Blue Shield, reported a similar jump in its "benefit expense ratio" to 88.9% in the second quarter, up from 86.3% in the same quarter last year. Both Centene and Elevance attributed the jump especially to their government-subsidized offerings under the Medicaid and Medicare programs. Molina Healthcare (MOH), which reported Q2 earnings earlier this month, reported a similar outlook, attributing its lowered earnings guidance to the same trend facing other medical insurers. "The short-term earnings pressure we are experiencing results from what we believe to be a temporary dislocation between premium rates and medical cost trend which has recently accelerated,' Molina CEO Joseph Zubretsky said in a statement. Elevance stock dropped by roughly 12% after its report earlier this month, while Molina stock dropped by roughly 8%. Both stocks have remained depressed since. Health Care (XLV) is the worst-performing sector in the S&P 500 this year. Centene stock dropped by roughly 15% in premarket trading after its earnings release before recovering to a positive gain of roughly 6% by the closing bell on Friday. The buoy was led by CEO Sarah London's announcement that Centene was reinstating earnings guidance after pulling this forecast earlier in the month. The company also reported revenue of $48.7 billion, which topped estimates for $44.2 billion, and said it expects to be able to raise the payments it gets from states for Medicaid plans, which would improve its margins. UnitedHealth's MCR challenge The premium-to-cost ratio will be closely watched at UnitedHealth Group (UNH), which refers to this measure as its "medical care ratio" (MCR) and is slated to release Q2 earnings next week. After seeing its medical care ratio rise to 85.1% in the second quarter last year, UnitedHealth is expected to see its ratio jump to 89.3% this year, according to Bloomberg consensus estimates. An increase like that would mean tighter margins and less overhead for a company that already slashed its forecast earlier this year. That news sent its stock price down by 22%, its biggest drop in a single day since 1998. "Management noted care activity trends continue to run ahead of its previous expectations driven by a greater than expected impact at UHC from new members, further acceleration of [Medicare Advantage] utilization and indications of potential broadening trend among adjacent, complex populations," Truist Securities analysts wrote in a May analyst note about UnitedHealth. Closely watched by investors and analysts will also be how UnitedHealth leadership addresses its disclosure Thursday morning that the insurer is facing and complying with a criminal and civil investigation by the Department of Justice over potential fraudulent billing practices in the insurer's Medicare Advantage program. The stock dropped 4.7% through Thursday trading after the disclosure. The probe comes after reporting by the Wall Street Journal earlier this year that documented the potentially fraudulent activity by UnitedHealth, among other medical insurers, which included insurers' staff doctors and nurses adding diagnoses to patients' profiles on top of those documented by the patients' doctors. UnitedHealth may have to answer investor inquiries about the investigation on its earnings call on Tuesday, though these are far from the only challenges facing the insurance giant. According to former federal prosecutor Scott Hogan, the DOJ's Medicare probe will be looking to establish a prolonged pattern of wrongdoing by the insurer. "If everything comes back good for the company, if the department [closes its investigation], I think the company will be able to reassure the marketplace," Hogan, who specialized in fraud investigations, told Yahoo Finance on Friday. Even if UnitedHealth is eventually cleared of wrongdoing, he said, "If the investigation takes next steps, whether it's a lawsuit or prolonged investigation, I don't think there are many companies that desire those kinds of headlines." Jake Conley is a breaking news reporter covering US equities for Yahoo Finance. Follow him on X at @byjakeconley or email him at Click here for in-depth analysis of the latest stock market news and events moving stock prices
Yahoo
13 minutes ago
- Yahoo
When does class start for students in the Wisconsin Rapids area for the 2025-26 school year?
WISCONSIN RAPIDS – Students, teachers, parents and administration staff are each recharging and preparing for the upcoming school year through the summer months. Several weeks of summer remain, but everyone is looking forward to the next school year in their own way. Here's when students are expected back in the classroom this fall in the Wisconsin Rapids area. Wisconsin Rapids Public Schools All grades up to 9 and new students: Sept. 2 Grades 10-12: Sept. 3 Grant Elementary School open house: Aug. 27 Lincoln High School schedule pickup: Aug. 20-21, 26 Find the 2025-26 school year calendar at Assumption Catholic Schools Seniors: Aug. 25 K-11 students: Aug. 27 Find the 2025-26 school year calendar at Adams-Friendship Area School District Grades 5-12: Sept. 3 5K students: Sept. 4 4K students: Sept. 8 Orientation day for 5K-fourth, fifth- and ninth-grade students: Sept. 2. Find the 2025-26 school year calendar at School District of Auburndale All students: Aug. 25, 1 p.m. dismissal Open house: Aug. 21 Find the 2025-26 school year calendar at Port Edwards School District All students: Sept. 2 Find the 2025-26 school year calendar under 'District' in the dropdown menu at School District of Nekoosa All students: Sept. 2 Find the 2025-26 school year calendar at School District of Pittsville All students: Sept. 2 Find the 2025-26 school year calendar at Exclusive report: $200 million AI data center no longer plans to open in Wisconsin Rapids. What we know. Exclusive report: East Jackson Street is set for reconstruction in Wisconsin Rapids. What to know so far. Erik Pfantz covers local government and education in central Wisconsin for USA TODAY NETWORK-Wisconsin and values his background as a rural Wisconsinite. Contact him at epfantz@ This article originally appeared on Wisconsin Rapids Daily Tribune: When does school start for students in Wisconsin Rapids for 2025? Solve the daily Crossword
